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Abstract
Background: The Revised National Tuberculosis Control Program (RNTCP) of India recommends follow-up sputum smear
examination at two months into the continuation phase of treatment. The main intent of this (mid-CP) follow-up is to detect
patients not responding to treatment around two-three months earlier than at the end of the treatment. However, the
utility of mid-CP follow-up under programmatic conditions has been questioned. We undertook a multi-district study to
determine if mid-CP follow-up is able to detect cases of treatment failures early among all types of patients with sputum
smear-positive TB.
Methodology: We reviewed existing records of patients with sputum smear-positive TB registered under the RNTCP in 43
districts across three states of India during a three month period in 2009. We estimated proportions of patients that could
be detected as a case of treatment failure early, and assessed the impact of various policy options on laboratory workload
and number needed to test to detect one case of treatment failure early.
Results: Of 10055 cases, mid-CP follow-up was done in 6944 (69%) cases. Mid-CP follow-up could benefit 117/8015 (1.5%)
new and 206/2040 (10%) previously-treated sputum smear-positive cases by detecting their treatment failure early. Under
the current policy, 31 patients had to be tested to detect one case of treatment failure early. All cases of treatment failure
would still be detected early if mid-CP follow-up were discontinued for new sputum smear-positive cases who become
sputum smear-negative after the intensive-phase of treatment. This would reduce the related laboratory workload by 69%
and only 10 patients would need to be tested to detect one case of treatment failure early.
Conclusion: Discontinuation of mid-CP follow-up among new sputum smear-positive cases who become sputum smear-
negative after completing the intensive-phase of treatment will reduce the laboratory workload without impacting overall
early detection of cases of treatment failure.
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Introduction
The World Health Organization (WHO) and India’s Revised
National Tuberculosis Control Programme (RNTCP) recommend
periodic sputum smear microscopy during the course of tubercu-
losis (TB) treatment to monitor individual patient progress and
assess overall programme performance [1,2]. One of these follow-
up microscopy examinations is scheduled between the 4
th and 6
th
month of anti-TB treatment, i.e. in the middle of the ‘continuation
phase’ (CP) of typical anti-TB treatment. The result of this (mid-
CP) follow-up examination may have clinical implications; a
patient found sputum smear-positive at the 5
th month of treatment
(or later) is considered as not responding to treatment (‘treatment
failure’) and is evaluated for possible drug resistance [2]. Further
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testing. Absence of mid-CP follow-up may therefore, in theory,
result in a missed opportunity for evaluation for drug-resistance, a
delay in treatment adjustments, and therefore poor treatment
outcomes.
However, the utility of mid-CP follow-up in India has been
questioned in a study from South India [3] where investigators
concluded that mid-CP follow-up was not likely to be useful except
in a small proportion of cases that remain sputum smear-positive
at the end of the intensive phase of treatment (IP). This study could
not influence policy on mid-CP follow-up, possibly because it was
done in a small geographic area during the initial years of the
RNTCP.
Discontinuation of mid-CP sputum smear examination offers
the potential advantage of saving laboratory workload and
patient inconvenience. The mid-CP follow-up accounts for
about one-third of all the follow-up microscopy workload on
laboratories. In India, patients must themselves bear the burden
of lost time and travel expenses necessitated by each follow-up
microscopy examination. With more than 800,000 sputum
smear-positive cases registered under the RNTCP each year [4],
the cumulative burden of this follow-up is substantial. We
undertook a multi-district study to determine if mid-CP follow-
up is of value to the RNTCP as measured by its contribution
towards early detection of patients who are not responding to
treatment.
Methods
Study Design
We conducted a descriptive study involving review of existing
records maintained under the RNTCP.
Setting
Bihar, a state in eastern India (population: 96 million),
Maharashtra, a state in western India (population: 111 million),
and Karnataka, a state in southern India (population: 59 million)
together account for approximately one-sixth of sputum smear-
positive cases notified in the country [4]. This study was conducted
in five districts of Bihar, seven districts of Maharashtra and all 31
districts of Karnataka.
Under the RNTCP, all patients with TB are treated with a
standardized short-course thrice-weekly intermittent regimen
under direct observation of a trained (DOT) provider. The
treatment consists of an intensive phase (IP) consisting of four to
five drugs in the initial two to three months and a continuation
phase (CP) consisting of two to three drugs for four to five
months, depending on the history of previous treatment. In
addition, cases that are sputum smear-positive at the end of IP,
receive a four week extension of the IP regimen. Follow-up
sputum smear microscopy is recommended at the end of IP,
extended-IP, mid-CP and at the end of treatment to assess
patients’ clinical progress (Figure 1). The DOT provider reminds
and motivates the patient to undergo the prescribed sputum
smear follow-ups at a Designated Microscopy Center (DMC) and
updates a treatment card with the follow-up results. The outcome
is assessed by a Medical Officer on the basis of record of
treatment and follow-ups maintained in the treatment cards. All
these events, from initiation of treatment to various follow-ups
and finally, the outcome, are transcribed into a TB register by
the treatment supervisor of that reporting unit. The quality of
sputum smear microscopy is assured by laboratory supervisors at
the district through a monthly random blinded quality assurance
process.
Study Period
We conducted the study duringSeptember 2010 to August 2011.
Study Population
All cases of sputum smear-positive TB registered for treatment
under the RNTCP during a three month period in 2009 [July to
September (Maharashtra and Bihar); April to June (Karnataka)] in
all the reporting units of selected districts were included in the
study. However, cases that were registered for treatment elsewhere
and later, got transferred-in [4] to the study reporting units, and
those that were prescribed Non-DOTS treatment regimen [4],
were excluded.
Sampling
No sampling was done. All eligible cases of sputum smear-
positive TB registered during the study period were included in the
study. Selection of States, districts and study period were based on
feasibility of data collection.
Study Variables
Data on type of case (new or previously-treated), result of sputum
smear microscopy at the end of IP, at the end of extended IP
(wherever applicable), at two months into CP and at end of
treatment, and outcome of treatment were collected. Results of
sputum smear microscopy were recorded as negative, positive, not
applicable, or not done. A positive result included all registered
grades (3+,2 +,1 + or Scanty) as defined under the program [4].
Missingentrieswithrespecttofollow-upresultswererecordedasnot
applicable(ifapatientcouldnotbeexpectedtoundergoaparticular
follow-up on account of death, default, failure or transfer to another
reportingunit),or,asnotdone.Outcomeoftreatmentwasrecorded
as cured, treatment completed, died, default, failure and transfer-
out, as per the standard WHO definitions [1]. If a case of treatment
Figure 1. Timing of follow-up sputum smear examinations.
Treatment duration and timing of follow-up sputum smear examina-
tions for new and previously-treated cases of tuberculosis, highlighting
the timing of the follow-up mid-continuation phase sputum smear
examination. The initial two-three month intensive phase (light blue
bars) is followed by a follow-up sputum smear examination (pink bars).
If the follow-up sputum smear examination is positive, an additional 1-
month extended-intensive phase treatment is given (dark blue bar),
with additional follow-up sputum smear examination. After the
intensive phase (or extended intensive phase), the continuation phase
of treatment (grey bars) is immediately begin. After two months of
continuation phase (i.e. between months 4 and 6), the mid-
continuation phase (mid-CP) follow-up sputum smear examination is
done (red bars, circled with dotted line). At the end of the continuation
phase, a final follow-up sputum smear examination is done.
doi:10.1371/journal.pone.0039296.g001
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follow-up rather than at the end of treatment, it was considered as
detected early. Conceptually, ‘early’ refers to the time gap between
the mid-CP and the end of treatment sputum smear examination,
and equates to around two months for new cases, and three months
for previously-treated cases (Figure 1).
Data Collection and Entry
In Bihar, the required data were extracted into a pre-structured
data collection format by the principal investigator from TB
registers after validating the results of follow-up sputum smear
examinations with TB laboratory registers. Data were then doubly
entered in Epi-data (Version 3.1) and the two data-sets were
compared for discrepancies, which were resolved by referring to
the hard copies of original data collection formats. The final
database was exported into MS Excel. Validated data from
Karnataka and Maharashtra were received in a similar format.
The three data-sets were finally collated and analyzed.
Data Analysis
We calculated the proportion of cases that underwent mid-CP
follow-up and the proportion of cases that were detected early as
treatment failure based on mid-CP follow-up. We also estimated
the additional number of cases detected early as treatment failure
if all cases had undergone mid-CP follow-up, assuming that all
cases with positive sputum smears at the end of treatment would
also have been sputum smear-positive in mid-CP follow-up. Lastly,
we estimated the number needed to test to detect one case of
treatment failure early, with different policy options related to
mid-CP follow-up.
Ethics Approval
Under the RNCTP, written consent of patient for storage and
future usage of his/her personal details is not taken as a routine.
However, personal details of patients are not shared with anybody
outside the care, support and treatment framework, without prior
consent of the patient.
For this study, which involved a review of routinely maintained
records under the RNTCP and did not involve patient interaction
in the process of data collection, individual patient consent was not
necessary. The study protocol was examined and approved, and
individual patient consent was determined to be unnecessary by
the Ethics Advisory Group of International Union Against
Tuberculosis and Lung Disease, and the Ethics Committee of
the National Tuberculosis Institute, Bangalore, India. Participa-
tion of U.S. Centers for Disease Control and Prevention (CDC) in
this project did not meet the definition of engagement in human
subjects’ research and separate institutional review board approval
was not required.
Results
A total of 12,558 cases of sputum smear-positive TB were
included in the study. As a result of death, default or transfer to
some other reporting unit, 2503 (20%) cases did not reach the 2
nd
month of CP (i.e. the time when mid-CP follow-up becomes due
under the RNTCP). Of the remaining 10,055 cases, all of which
should have gotten mid-CP follow-up examination as per the
RNTCP guidelines, mid-CP follow-up was documented in 6944
(69%) cases. Of these, 280 (4%) cases were detected as treatment
failure on the basis of mid-CP follow-up, around two-three months
earlier than if detected on the basis of sputum smear examination
at the end of the treatment.
Of the 8015 new cases with sputum smear-positive TB, 5550
(69%) cases underwent mid-CP follow-up. Of these, 106 (2%) were
detected early as cases of treatment failure (Figure 2). If the
remaining 2465 cases had undergone mid-CP follow-up, and
assuming that all cases with positive sputum smears at the end of
treatment would also have been sputum smear-positive in mid-CP
follow-up, an estimated maximum of 11 additional cases of
treatment failure could have been detected early (Figure 2). So, at
Figure 2. Flow of cases of sputum smear-positive Tuberculosis as per successive sputum smear microscopy results. Mid-CP follow-up
refers to the sputum smear microscopy which is scheduled between the 4
th and 6
th month of anti-TB treatment, i.e. in the middle of the ‘continuation
phase’ (CP) of typical anti-TB treatment. Cases that are found to be smear-positive at 5
th month or later are considered as not responding to
treatment (‘treatment failure’). Numerals shown in rectangular boxes refer to number of cases with treatment failure who were detected two-three
months earlier than at the end of treatment as they were smear-positive in mid-CP follow-up at or beyond 5
th month of anti-TB treatment. Numerals
shown in clear ovals refer to number of cases with treatment failure that were detected only at the end of treatment because they were either smear-
negative in mid CP follow-up, or had a smear-positive mid-CP result before 5
th month of anti-TB treatment. Numerals shown in shaded ovals refer to
number of cases with treatment failure who missed their mid-CP follow-up scheduled at or beyond 5
th month of treatment. These cases could have
been detected two-three months earlier had they undergone mid-CP follow-up and were found to be smear-positive.
doi:10.1371/journal.pone.0039296.g002
Table 1. Impact of various policy options with regard to mid-CP follow-up on the number of cases of tuberculosis treatment
failures detected early
1 and laboratory workload.
Policy Options for mid-CP follow-up Total patients tested (%)
2
Cases of Treatment
Failure detected early
1
(Gain/Loss)
3
Number needed to test
to detect one case of
treatment failure early
1
Continue as per present guideline 10055 (100) 323 31
Discontinue in new end-IP negative cases 3154 (31) 323 10
Discontinue in all new cases 2040 (20) 206 (2117) 10
Discontinue in all end-IP negative cases 1531 (15) 214 (2109) 7
Schedule mid-CP follow-up to 5th month for all cases 10055 (100) 421 (+98) 24
1Detected as a case of treatment failure around two-three months earlier than if detected at the end of the treatment.
2Percentage calculated by taking follow-up required under present policy as denominator.
3Gain/Loss in absolute numbers indicated respectively by a positive or a negative sign; CP-Continuation Phase of TB treatment.
doi:10.1371/journal.pone.0039296.t001
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Of the 2040 previously-treated cases with sputum smear-
positive TB, 1394 (68%) cases underwent mid-CP follow-up. Of
these, 174 (12%) were detected early as cases of treatment failure
(Figure 2). If the remaining 646 cases had undergone mid-CP
follow-up, and assuming that all cases with positive sputum smears
at the end of treatment would also have been sputum smear-
positive in mid-CP follow-up, an estimated maximum of 32
additional cases of treatment failure could have been detected
early (Figure 2). So, at best, mid-CP follow-up could have
benefitted up to 206 of 2040 (10%) previously-treated cases.
Overall, if all 10,055 cases with sputum smear-positive TB had
undergone mid-CP follow-up, up to 323 (3.2%) cases could have
benefitted from mid-CP follow-up.
As per present policy, about 31 patients need to be tested by
mid-CP follow-up to detect one case of treatment failure early
(Table 1). Discontinuation of mid-CP follow-up in new sputum
smear-positive cases who were sputum smear-negative at the end
of IP would achieve the same at a much reduced effort with a
number needed to test of just 10. However, discontinuation of
mid-CP follow-up in all cases (new and previously-treated) who
became sputum smear-negative at end of IP (end-IP negative), or,
in all new cases, could have led to a delay in declaration of 109 to
117 cases, respectively, as treatment failure (Table 1; Figure 2). By
scheduling mid-CP follow-up at the 5
th month, 98 additional cases
of treatment failure could have been detected early without
increasing the overall laboratory workload (Table 1; Figure 2).
Discontinuation of mid-CP follow-up among the 6901 new
sputum smear-positive cases who were sputum smear-negative at
the end of IP would delay by two months the opportunity of
evaluation of possible drug resistance for 64 (,1%) cases that were
found sputum smear-positive in mid-CP follow-up.
Discussion
We found that, at best, only 117/8015 (1.5%) new and 206/
2040 (10%) previously-treated cases of sputum smear-positive TB
could have benefitted from follow-up sputum smear examination
at two months into the continuation phase of treatment (mid-CP
follow-up). As per present policy, the program needs to undertake
mid-CP follow-up in about 31 cases to detect one case of treatment
failure early. The number needed to test to detect a single case of
treatment failure early could be reduced to as low as 7 (up to 77%
reduction) by considering different policy options for mid-CP
follow-up. Given the burden of this follow-up under the RNTCP,
the program should consider a policy change.
Discontinuing mid-CP follow-up among new sputum smear-
positive TB cases whose sputum smear is negative at the end of IP
appears to be the best option, because a similar number of cases of
treatment failure would have been detected early as detected
under current policy while reducing the total workload by two-
thirds. This policy option would also have substantially reduced
the patient-incurred costs involved in travelling to a microscopy
centre for follow-up sputum smear examination.
Discontinuation of mid-CP follow-up among all new cases, or
among all (new and previously-treated) end-IP sputum smear-
negative cases, would have decreased the overall laboratory
workload as well as the effort required to detect one case of
treatment failure early. However, this could have led to two-three
months delay in detection of a significant number of cases of
treatment failure, thus, delaying drug susceptibility testing and
necessary treatment adjustments.
Scheduling mid-CP follow-up sputum smear examination at the
5
th month instead of two months into CP is a tempting option.
This policy change would have allowed for early detection of 98
additional cases of treatment failure without increasing the
laboratory workload any further. But ascertaining the 5
th month
of treatment may be difficult for the DOT provider. The current
recommended practice is to send the patient for mid-CP follow-up
at the time of dispensing the 8
th weekly blister-pack, which roughly
equals to two months into CP. Counting empty blister-packs is
easier than counting months from the date of starting treatment
for the DOT providers who may have limited education.
As the present guideline of the RNTCP is to evaluate each
follow-up sputum-smear positive case for possible drug resistance,
will the recommended policy change lead to missed opportunities
for detecting multi-drug resistance? The study data suggest that
this could have happened for a small minority [,64/6901 (1%)],
but these cases would have had another opportunity two months
later, if found sputum smear-positive at the end of treatment. We
believe this risk to be worth taking, given the substantial reduction
in laboratory workload.
This study was conducted in 170 reporting units of 43 districts
spread across three states of the country and we believe that it is
indicative of the national situation. A key limitation of this study is
that uptake of mid-CP follow-up was low (69%), as is the reality
under routine programme conditions. For this reason, we
estimated the additional benefit by assuming the best case
scenario, and still found little utility of mid-CP follow-up among
new cases with sputum smear-positive TB. The reasons for the low
uptake of mid-CP follow-up were beyond the scope of the current
study and need to be addressed by future research.
Conclusion
We believe the national TB control programme in India should
consider a change in policy regarding mid-CP follow-up. Taking
program priorities and field conditions into view, discontinuation
of mid-CP follow-up among those new sputum smear-positive TB
cases who become sputum smear-negative after the intensive-
phase of treatment, appears to be the best option. This will save
human and material resources for the program, without delaying
identification of multidrug resistant cases.
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